High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
Gaucher disease (GD), the most common lysosomal storage disorder, results from the inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCase). Previously, wildtype GCase was used for high throughput screening (HTS) of large collections of compounds to identify small molecule chaperones...
Main Authors: | Ehud Goldin, Wei Zheng, Omid Motabar, Noel Southall, Jae Hyuk Choi, Juan Marugan, Christopher P Austin, Ellen Sidransky |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3260169?pdf=render |
Similar Items
-
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
by: Makaila L. Furderer, et al.
Published: (2022-05-01) -
Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
by: Trapero, A, et al.
Published: (2012) -
Effect of macrophage-targeted glucocerebrosidase(alglucerase) on hypolipidaemia of type 1 Gaucher disease(GD)
by: Mistry, P, et al.
Published: (1997) -
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson’s Disease
by: Alena E. Kopytova, et al.
Published: (2023-05-01) -
Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
by: Trapero, A, et al.
Published: (2011)